Suppr超能文献

肿瘤学中的正电子发射断层扫描(PET):它会取代其他检查方式吗?

PET in oncology: will it replace the other modalities?

作者信息

Hoh C K, Schiepers C, Seltzer M A, Gambhir S S, Silverman D H, Czernin J, Maddahi J, Phelps M E

机构信息

Department of Molecular and Medical Pharmacology, UCLA School of Medicine 90095-6942, USA.

出版信息

Semin Nucl Med. 1997 Apr;27(2):94-106. doi: 10.1016/s0001-2998(97)80042-6.

Abstract

Medical imaging technology is rapidly expanding and the role of each modality is being redefined constantly. PET has been around since the early sixties and gained clinical acceptance in oncology only after an extreme number of scientific publications. Although PET has the unique ability to image biochemical processes in vivo, this ability is not fully used as a clinical imaging tool. In this overview, the role of PET in relation to other tumor imaging modalities will be discussed and the reported results in the literature will be reviewed. In predicting the future of PET, technical improvements of other imaging modalities need to be dealt with. The fundamental physical principles for image formation with computed tomography (CT), ultrasound (US), magnetic resonance imaging (MRI), photon-emission tomography (PET), and single photon emission CT (SPECT) will not change. The potential variety of radiopharmaceuticals which may be developed is unlimited, however, and this provides nuclear imaging techniques with a significant advantage and adaptive features for future biologic imaging. The current applications of PET in oncology have been in characterizing tumor lesions, differentiating recurrent disease from treatment effects, staging tumors, evaluating the extent of disease, and monitoring therapy. The future developments in medicine may use the unique capabilities of PET not only in diagnostic imaging but also in molecular medicine and genetics. The articles discussed in this review were selected from a literature search covering the last 3 years, and in which comparisons of PET with conventional imaging were addressed specifically. PET studies with the glucose analogue fluorine-18-labeled deoxyglucose (FDG) have shown the ability of detecting tumor foci in a variety of histological neoplasms such as thyroid cancer, breast cancer, lymphoma, lung cancer, head and neck carcinoma, colorectal cancer, ovarian carcinoma, and musculoskeletal tumors. Also, the contribution of the whole body PET (WBPET) imaging technique in diagnosis will be discussed. In the current health care environment, a successful imaging technology must not only change medical management but also demonstrate that those changes improve patient outcome.

摘要

医学成像技术正在迅速发展,每种成像方式的作用也在不断被重新定义。正电子发射断层显像(PET)自20世纪60年代初就已出现,经过大量科学出版物发表后才在肿瘤学领域获得临床认可。尽管PET具有在体内对生物化学过程进行成像的独特能力,但这种能力在临床成像工具中的应用尚未得到充分发挥。在本综述中,将讨论PET相对于其他肿瘤成像方式的作用,并对文献中报道的结果进行回顾。在预测PET的未来时,需要考虑其他成像方式的技术改进。计算机断层扫描(CT)、超声(US)、磁共振成像(MRI)、正电子发射断层显像(PET)和单光子发射计算机断层扫描(SPECT)的图像形成基本物理原理不会改变。然而,可能开发的放射性药物种类是无限的,这为核成像技术提供了显著优势和适应未来生物成像的特性。PET目前在肿瘤学中的应用包括对肿瘤病变进行特征描述、区分复发性疾病与治疗效果、肿瘤分期、评估疾病范围以及监测治疗。医学的未来发展可能不仅会在诊断成像中利用PET的独特能力,并将其应用于分子医学和遗传学。本综述中讨论的文章是从过去3年的文献搜索中挑选出来的,其中专门涉及PET与传统成像比较的内容。使用葡萄糖类似物氟-18标记的脱氧葡萄糖(FDG)进行的PET研究表明,PET能够检测多种组织学类型的肿瘤病灶,如甲状腺癌、乳腺癌、淋巴瘤、肺癌、头颈癌、结直肠癌、卵巢癌和肌肉骨骼肿瘤。此外,还将讨论全身PET(WBPET)成像技术在诊断中的作用。在当前的医疗环境中,一种成功的成像技术不仅必须改变医疗管理方式,还必须证明这些改变能够改善患者的治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验